Redmile Group LLC Has $11.33 Million Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Redmile Group LLC boosted its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 22.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 261,803 shares of the company's stock after buying an additional 48,779 shares during the period. Redmile Group LLC owned approximately 0.94% of Establishment Labs worth $11,328,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ESTA. First Turn Management LLC bought a new position in Establishment Labs in the second quarter valued at approximately $16,812,000. Sofinnova Investments Inc. boosted its holdings in shares of Establishment Labs by 204.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock valued at $19,505,000 after purchasing an additional 288,082 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in Establishment Labs in the second quarter valued at about $5,829,000. Millennium Management LLC grew its position in Establishment Labs by 49.8% in the second quarter. Millennium Management LLC now owns 273,605 shares of the company's stock valued at $12,433,000 after acquiring an additional 90,943 shares during the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in Establishment Labs by 10.7% during the third quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company's stock worth $34,326,000 after acquiring an additional 76,959 shares in the last quarter. 72.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ESTA shares. JPMorgan Chase & Co. cut their price objective on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating on the stock in a report on Wednesday, August 7th. Citigroup increased their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. Stephens raised Establishment Labs to a "strong-buy" rating in a report on Monday. Finally, BTIG Research increased their price target on Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Establishment Labs has an average rating of "Buy" and an average target price of $60.60.

Establishment Labs Trading Down 5.4 %

ESTA stock traded down $2.38 during midday trading on Thursday, hitting $41.79. The stock had a trading volume of 337,647 shares, compared to its average volume of 387,811. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The firm has a market cap of $1.17 billion, a P/E ratio of -16.20 and a beta of 1.16. The business has a fifty day moving average price of $43.50 and a two-hundred day moving average price of $44.53. Establishment Labs Holdings Inc. has a 1-year low of $22.05 and a 1-year high of $60.12.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.